LebastchiAH, GeorgeAK, PolascikTJ, et al.Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: An International Multidisciplinary Consensus. Eur Urol, 2020; 78:371–378.
2.
HamdyFC, DonovanJL, LaneJA, et al.10-Year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med, 2016; 375:1415–1424.
3.
Prostate Cancer: Clinically Localized Guideline—American Urological Association. Available at https://www.auanet.org/guidelines/prostate-cancer-clinically-localized-guideline#x6910 (last accessed March13, 2021).
4.
RossHM, KryvenkoON, CowanJE, SimkoJP, WheelerTM, EpsteinJI. Do adenocarcinomas of the prostate with Gleason score (GS) ≤6 have the potential to metastasize to lymph nodes?. Am J Surg Pathol, 2012; 36:1346–1352.
5.
KlotzL, VespriniD, SethukavalanP, et al.Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol, 2015; 33:272–277.
6.
TosoianJJ, MamawalaM, EpsteinJI, et al.Active Surveillance of Grade Group 1 prostate cancer: Long-term outcomes from a large prospective cohort. Eur Urol, 2020; 77:675–682.
7.
BellarditaL, ValdagniR, van den BerghR, et al.How does active surveillance for prostate cancer affect quality of life? A systematic review. Eur Urol, 2015; 67:637–645.
8.
DinizCP, LandisP, CarterHB, EpsteinJI, MamawalaM. Comparison of biochemical recurrence-free survival after radical prostatectomy triggered by grade reclassification during active surveillance and in men newly diagnosed with similar grade disease. J Urol, 2017; 198:608–613.
9.
ValerioM, CerantolaY, EggenerSE, et al.New and established technology in focal ablation of the prostate: A systematic review. Eur Urol, 2017; 71:17–34.
10.
AzzouziA-R, VincendeauS, BarretE, et al.Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): An open-label, phase 3, randomised controlled trial. Lancet Oncol, 2017; 18:181–191.
